Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases
Anticancer Research · 2025
DOI: 10.21873/anticanres.17451 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Anticancer Research, 2025. Verfasst von Gaku Yamamichi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Bone Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Nivolumab.
Abstract (Originalsprache)
BACKGROUND/AIM: Combination therapy with immune checkpoint inhibitors has become the standard first-line treatment for metastatic renal cell carcinoma (mRCC), leading to changes in second-line treatment options, such as nivolumab or tyrosine kinase inhibitors (TKIs). However, very few studies have compared the efficacy of these drugs in patients with mRCC, particularly those with bone metastases (BM), which are associated with a poor prognosis. This study compared the efficacy of nivolumab and TKIs as second-line treatments for mRCC patients with BM and examined the microenvironments of primary tumors and BM lesions. PATIENTS AND METHODS: This multi-institutional retrospective study included 87 mRCC patients with BM who received either nivolumab or TKIs as second-line treatments. We analyzed tumor-infiltrating immune cells expressing CD8 and CD20, along with PD-L1, HIF2α, c-MET, VEGFR2, and AXL, in primary tumors and BM sites using immunohistochemistry. RESULTS: This analysis indicated that poor-risk classification, as per the International Metastatic RCC Database Consortium criteria (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.
- Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan kato@uro.med.osaka-u.ac.jp.
- Department of Urology, Osaka General Medical Center, Osaka, Japan.
- Department of Urology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
- Department of Urology, Osaka Police Hospital, Osaka, Japan.
- Department of Urology, Osaka Rosai Hospital, Osaka, Japan.
Zitieren
APA
Yamamichi, G., Kato, T., Yoshimura, A., Tani, M., Horibe, Y., Liu, Y., Sassi, N., Okuda, Y., Oka, T., Uemura, T., Yamamoto, A., Ishizuya, Y. U., Hayashi, T., Yamamoto, Y., Hatano, K., Kawashima, A., Takao, T., Nishimura, K., Takada, S., …, & Nonomura, N. (2025). Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases. Anticancer Research. https://doi.org/10.21873/anticanres.17451
Vancouver
Yamamichi G, Kato T, Yoshimura A, Tani M, Horibe Y, Liu Y, et al. Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases. Anticancer Research. 2025. doi:10.21873/anticanres.17451
BibTeX
@article{Yamamichi2025,
author = {Yamamichi, Gaku and Kato, Taigo and Yoshimura, Akihiro and Tani, Masaru and Horibe, Yuki and Liu, Yutong and Sassi, Nesrine and Okuda, Yohei and Oka, Toshiki and Uemura, Toshihiro and Yamamoto, Akinaru and Ishizuya, Y U and Hayashi, Takuji and Yamamoto, Yoshiyuki and Hatano, Koji and Kawashima, Atsunari and Takao, Tetsuya and Nishimura, Kensaku and Takada, Shingo and Tsujihata, Masao and Nonomura, Norio},
title = {Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17451}
}
EUVIMED